Champions Oncology, Inc. (CSBR)
5.18
+0.18
(+3.60%)
USD |
NASDAQ |
Sep 02, 13:18
Champions Oncology Research and Development Expense (Annual) : 9.084M for April 30, 2026
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| April 30, 2026 | 9.084M |
| April 30, 2025 | 6.825M |
| April 30, 2024 | 9.544M |
| April 30, 2023 | 11.54M |
| April 30, 2022 | 9.374M |
| April 30, 2021 | 7.196M |
| April 30, 2020 | 5.853M |
| April 30, 2019 | 4.798M |
| April 30, 2018 | 4.401M |
| April 30, 2017 | 4.293M |
| April 30, 2016 | 4.194M |
| April 30, 2015 | 4.845M |
| April 30, 2014 | 2.265M |
| April 30, 2013 | 1.92M |
| April 30, 2012 | 2.937M |
| Date | Value |
|---|---|
| April 30, 2011 | 2.951M |
| April 30, 2010 | 2.695M |
| April 30, 2009 | 1.721M |
| April 30, 2008 | 0.1997M |
| April 30, 2007 | 0.00 |
| April 30, 2006 | 0.00 |
| April 30, 2005 | 0.00 |
| April 30, 2004 | 0.00 |
| April 30, 2003 | 0.00 |
| April 30, 2002 | 0.00 |
| April 30, 2001 | 0.00 |
| April 30, 2000 | 0.00 |
| April 30, 1999 | 0.00 |
| April 30, 1998 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Medpace Holdings, Inc. | -- |
| Avantor, Inc. | -- |
| Personalis, Inc. | 50.26M |
| Adaptive Biotechnologies Corp. | 83.81M |
| 10X Genomics, Inc. | 238.63M |